PRQR
ProQR Therapeutics N.V.NASDAQHealthcare$1.71+0.00%ClosedMarket Cap: $180.2M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
3.27
P/S
10.39
EV/EBITDA
-2.15
DCF Value
$-44.84
FCF Yield
-32.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
95.8%
Operating Margin
-273.0%
Net Margin
-264.9%
ROE
-65.1%
ROA
-37.4%
ROIC
-51.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $4.6M | 85.5% | $-9.0M | $-8.8M | $-0.09 | — |
| FY 2025 | $15.3M | 83.0% | $-42.2M | $-40.5M | $-0.38 | — |
| Q3 2025 | $2.9M | 100.0% | $-11.3M | $-11.0M | $-0.10 | — |
| Q2 2025 | $3.8M | 100.0% | $-12.2M | $-12.2M | $-0.12 | — |
| Q1 2025 | $4.5M | 100.0% | $-10.8M | $-10.1M | $-0.10 | — |
| Q4 2024 | $4.3M | 100.0% | $-10.1M | $-9.3M | $-0.11 | — |
| FY 2024 | $18.9M | 100.0% | $-30.5M | $-27.8M | $-0.34 | — |
| Q3 2024 | $3.8M | 100.0% | $-8.7M | $-8.1M | $-0.10 | — |
| Q2 2024 | $6.3M | 100.0% | $-3.6M | $-2.7M | $-0.03 | — |
| Q1 2024 | $4.5M | 100.0% | $-8.1M | $-7.7M | $-0.09 | — |
| Q4 2023 | $3.3M | 100.0% | $-6.3M | $-5.5M | $-0.07 | — |
| FY 2023 | $6.5M | 100.0% | $-31.9M | $-28.1M | $-0.35 | — |